SPEEDCELL responds to Europe's medicine shortages by transforming cells-based manufacturing into a rapid, scalable, and cost-effective platform for vaccines and monoclonal antibodies (mAbs). Aligned with the Pharmaceutical Strategy for Europe and HERA’s crisis preparedness goals, the project will optimise cell line development and production processes, targeting the 100 Days Goal for vaccine and therapeutic deployment in health emergencies. By boosting manufacturing capacity and process innovation, SPEEDCELL strengthens Europe’s health resilience and supply security.
- Beneficiaries
Coordinators: Laboratorios Hipra Sa
Participants: Hipra Biotech Services - S.A.U. - Hipra Human Health Sl - Hipra Scientific Sl - Hipra Sociedad Anonima
- Project Location
Spain
- EU funding
€ 3 956 031.39
- Funding source
Other STEP stories
PharmSD 3.0 will develop an integrated, continuous-pharmaceutical spray drying process to enhance efficiency, scalability, and cost-effectiveness.
This project develops an AI and robotic driven, decentralised pharmaceutical EU manufacturing platform to enhance crisis preparedness.
SmartNEBI will develop a sustainable, enzyme-based synthesis of heart-medicine nebivolol to enhance sustainability, scalability, and EU pharmaceutical sovereignty.